XTL Biopharma Faces Nasdaq Minimum Bid Price Deficiency
Ticker: XTLB · Form: 6-K · Filed: Dec 29, 2025 · CIK: 1023549
| Field | Detail |
|---|---|
| Company | Xtl Biopharmaceuticals Ltd (XTLB) |
| Form Type | 6-K |
| Filed Date | Dec 29, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bearish |
Sentiment: bearish
Topics: listing-deficiency, nasdaq, regulatory
Related Tickers: XTLB
TL;DR
Nasdaq says XTL Bio's stock price is too low, might get delisted.
AI Summary
On December 24, 2025, XTL Biopharmaceuticals Ltd. received a notification letter from Nasdaq Listing Qualifications concerning a minimum bid price deficiency. The company is required to meet the minimum bid price requirement to remain listed on the Nasdaq Stock Market.
Why It Matters
Failure to regain compliance with Nasdaq's minimum bid price rule could lead to the delisting of XTL Biopharmaceuticals' stock, impacting its liquidity and investor confidence.
Risk Assessment
Risk Level: medium — A minimum bid price deficiency poses a direct threat to the company's listing on a major stock exchange, which can significantly impact its valuation and investor accessibility.
Key Players & Entities
- XTL Biopharmaceuticals Ltd. (company) — The company that received the notification.
- Nasdaq Stock Market LLC (company) — The exchange that issued the deficiency notification.
- December 24, 2025 (date) — Date the notification letter was received.
FAQ
What is the specific deficiency XTL Biopharmaceuticals Ltd. was notified of by Nasdaq?
XTL Biopharmaceuticals Ltd. was notified of a minimum bid price deficiency by The Nasdaq Stock Market LLC.
When did XTL Biopharmaceuticals Ltd. receive this notification?
The company received the notification letter on December 24, 2025.
What is the consequence of failing to meet the minimum bid price requirement?
Failure to meet the minimum bid price requirement could result in the company not remaining listed on The Nasdaq Stock Market.
Which exhibit contains the press release regarding this notification?
The press release is furnished as Exhibit 99.1.
What is the filing form type and submission date?
The filing form type is 6-K and it was filed as of December 29, 2025.
Filing Stats: 208 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2025-12-29 16:05:16
Filing Documents
- ea0271127-6k_xtlbio.htm (6-K) — 10KB
- ea027112701ex99-1_xtlbio.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 9KB
- 0001213900-25-126039.txt ( ) — 34KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XTL BIOPHARMACEUTICALS LTD. Date: December 29, 2025 By: /s/ Noam Band Noam Band Chief Executive Officer 2